Study to Evaluate the Exposure of Rifabutin Administered in an Alternate Regimen in Combination With Atazanavir and Ritonavir Healthy Subjects.

Trial Profile

Study to Evaluate the Exposure of Rifabutin Administered in an Alternate Regimen in Combination With Atazanavir and Ritonavir Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jan 2013

At a glance

  • Drugs Rifabutin (Primary) ; Atazanavir; Ritonavir
  • Indications HIV-1 infections; Mycobacterium avium complex infections; Tuberculosis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 28 Jun 2011 The study was stopped due to severe declines in neutrophil counts that were reported in more patients who received combination treatment.
    • 28 Jun 2011 Results published in the Journal of Antimicrobial Chemotherapy.
    • 01 Oct 2008 Actual patient number changed from 84 to 33 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top